Mark Cuban says he doesn’t trade the stock market like he used to, but he’s still sticking with these favorites
- A ‘powerful force’ will determine what happens next in the stock market, Wharton professor predicts
- Why the stock market’s record-breaking rally has investors on the cusp of ‘euphoria’
- Stocks will head higher until there’s a reason, besides COVID-19, to stop, one analyst says
- Stocks push higher; S&P 500 and Nasdaq clinch new intraday records
I’m a 57-year-old nurse with no retirement savings and I want to retire within seven years. What can I do?
- I’m 52, won’t live past 80 and have $1.6 million. ‘I am tired of both the rat race and workplace politics.’ Should I retire?
- I’m retired, my wife isn’t — how should we pay off our $60,000 mortgage before she retires?
- Opinion: This eye-opening experience has me rethinking how Social Security figures into my retirement planning
My husband wants 50% of my mother’s inheritance because he earns more than me. I said no. Am I being unreasonable?
I said I was willing to get a money manager and set up a retirement account in both of our names. I’ve always worked, even while raising our daughter.
Moderna's stock rises after it says COVID-19 vaccine candidate produced antibodies in older patients
Shares of Moderna Inc. undefined gained 5.2% in trading on Wednesday after a company executive told a government advisory committee that its experimental COVID-19 vaccine had triggered antibodies in elderly patients. Dr. Jacqueline Miller, the company's SVP of infectious disease development, told the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices that neutralizing antibody titers were reported in all age groups that are currently being studied: 18 to 55 years old, 56 to 70 years old, and 71 years and older. This is the first time that Moderna has released data about how its vaccine candidate has performed in an older patient population; the data it shared about how the investigational vaccine fared in the Phase 1 trial was for people between the ages of 18 and 55 years old. Moderna's stock is up 251.2% year-to-date, compared with the S&P 500 undefined, which is up 6.6%.
Oxford’s virus vaccine faces boycott on links to aborted foetus
The concerns expressed are in relation to a commonly used cell line derived from foetal kidney cells
